Dialysis News and Research

Latest Dialysis News and Research

Intensive glycemic control not associated with reduced risk of kidney failure in type-2 diabetics

Yale School of Medicine researchers have found that intensively controlling glucose (glycemic) levels in type-2 diabetes patients may not reduce the risk of kidney failure. The study, which is a review of data from seven clinical trials, is published in the May 28 issue of Archives of Internal Medicine.

29 May 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

Peritonitis commonly arises in the weeks before many dialysis patients die

An infection called peritonitis commonly arises in the weeks before many dialysis patients die, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

25 May 2012

First study to examine how patients and families are soliciting living kidney donors on Facebook

Loyola University Medical Center researchers are reporting one of the first studies to examine how patients and families are soliciting living kidney donors on Facebook.

24 May 2012

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.

24 May 2012

FMCNA announces new educational resources to enhance RightStart

Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, announced today new educational resources to enhance RightStart™, its innovative program designed to educate and empower new dialysis patients.

24 May 2012

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.

23 May 2012

Billion-dollar Davita deal highlights movement toward mergers, accountable care organizations

This particular deal, in which DaVita will acquire HealthCare Partners, will enable the dialysis services provider to offer a more integrated group of services that fall under the ACO model that the government is trying to encourage.

23 May 2012

“Networks” succeed in finding kidney donors: John Hopkins program reports

Johns Hopkins researchers say a program they developed that uses personal advocates and community networks to find organ donors for friends and loved ones who need kidney transplants resulted in success for nearly half of the participants in its trial run.

22 May 2012

First Edition: May 22, 2012

Today's headlines include reports about a lawsuit brought by Catholic organizations against the Obama administration's contraception coverage rule and a new recommendation on PSA screening by the U.S. Preventive Services Task Force.

22 May 2012

One type of open heart surgery is likely safer than the other for CKD patients

One type of open heart surgery is likely safer than the other for chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

18 May 2012

Medgenics’ EPODURE receives FDA clearance to proceed into clinical trials

Medgenics, Inc., developer of the novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the U.S. Food and Drug Administration to proceed with a Phase IIb clinical trial of EPODURE for the treatment of anemia in patients undergoing renal dialysis.

18 May 2012

Dialysis patients can benefit from talking control support therapy

The constant health education that dialysis patients receive can lead to boredom and noncompliance. But a Loyola University Medical Center study has found that brief, casual chats can be a significant benefit to patients.

17 May 2012

Kidney transplants more frequent among NxStage home hemodialysis patients

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on findings of the Chronic Disease Research Group (CDRG) study showing that patients receiving daily, or more frequent, home hemodialysis with the NxStage System One are more likely to receive a kidney transplant when compared with conventional thrice-weekly dialysis, particularly in patients not on the transplant waitlist at initiation of daily home hemodialysis.

14 May 2012

3SBio first quarter total net revenues increase 24.5% to RMB147.2M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012.

14 May 2012

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules. In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

11 May 2012

Rule change has consequences for dialysis patients

A shift last year by the federal government in how it pays for drugs to treat dialysis patients may have had an unintended and potentially dire consequence, according to new research: a significant jump in blood transfusions for patients who now may not be getting enough of the medications.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Cardionovum to introduce two DEB dilatation catheter product families

Cardionovum GmbH will launch two drug-eluting balloon (DEB) dilatation catheter product families at next week's EuroPCR 2012 congress: Paclitaxel-coated drug-eluting balloons for coronary and peripheral applications.

11 May 2012

A Better Method for Diagnosing Kidney Disease

Assessing glomerular filtration rate (GFR) using kidney filtration markers in blood is the standard means for determining kidney function, diagnosing kidney disease and measuring its progression. A higher filtration rate indicates healthy kidney function, while a lower rate points to various stages of kidney disease. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the new CKD-EPI equation for calculating GFR is a better predictor of risk for kidney disease and death compared to the most widely used method. The findings suggest that switching to the CKD-EPI equation for calculating GFR could focus efforts more efficiently, and improve assessment of patient future risk and treatment of kidney disease. The study is published in the May 9 edition of JAMA.

10 May 2012